Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort
{{output}}
Background: The IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as first-line standard of care for unresectable hepatocellular carcinoma (HCC), demonstrating superior overall survival (OS) and progression-fre... ...
